Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
News|Articles|April 1, 2026
Middle East Disruption Impacts 6.7% of Global Clinical Trials, With Phase 3 Studies Most Affected
Author(s)Pearl Steinzor
Fact checked by: Christina Mattina
Evaluation of more than 65,000 trials and 350,000 investigator sites highlights significant exposure in oncology and late-stage development.
Advertisement
Advertisement
The ongoing disruption in the Middle East is affecting a meaningful portion of global clinical research, with 6.7% of active trials and thousands of investigator sites exposed to regional instability, new insights from Phesi reveal.1
Related to this article
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
A meta-analysis found teleophthalmology satisfaction comparable to in-person eye care, but showed a gap between recommending it and reusing it.
Advertisement
Advertisement